ATE494362T1 - Verfahren zur reinigung von adenovirus - Google Patents

Verfahren zur reinigung von adenovirus

Info

Publication number
ATE494362T1
ATE494362T1 AT07100409T AT07100409T ATE494362T1 AT E494362 T1 ATE494362 T1 AT E494362T1 AT 07100409 T AT07100409 T AT 07100409T AT 07100409 T AT07100409 T AT 07100409T AT E494362 T1 ATE494362 T1 AT E494362T1
Authority
AT
Austria
Prior art keywords
virus
purifying
particles
levels
robustly
Prior art date
Application number
AT07100409T
Other languages
English (en)
Inventor
John O Konz
Ann Lee
Aaron Goerke
Chi Shung Brian To
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29549953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494362(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE494362T1 publication Critical patent/ATE494362T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
AT07100409T 2002-05-14 2003-05-13 Verfahren zur reinigung von adenovirus ATE494362T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38033202P 2002-05-14 2002-05-14

Publications (1)

Publication Number Publication Date
ATE494362T1 true ATE494362T1 (de) 2011-01-15

Family

ID=29549953

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03726841T ATE360683T1 (de) 2002-05-14 2003-05-13 Verfahren zur reinigung von adenovirus
AT07100409T ATE494362T1 (de) 2002-05-14 2003-05-13 Verfahren zur reinigung von adenovirus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03726841T ATE360683T1 (de) 2002-05-14 2003-05-13 Verfahren zur reinigung von adenovirus

Country Status (9)

Country Link
US (3) US20050196854A1 (de)
EP (2) EP1506287B1 (de)
AT (2) ATE360683T1 (de)
AU (1) AU2003229060A1 (de)
DE (2) DE60335672D1 (de)
DK (1) DK1506287T3 (de)
ES (2) ES2357366T3 (de)
PT (1) PT1506287E (de)
WO (1) WO2003097797A2 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360683T1 (de) * 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
BRPI0511764B8 (pt) * 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
AU2005305347A1 (en) * 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
JP2008538894A (ja) * 2005-02-11 2008-11-13 メルク エンド カムパニー インコーポレーテッド アデノウイルス血清型２６ベクター、核酸およびそれにより製造されたウイルス
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
US7673757B2 (en) 2006-02-17 2010-03-09 Millipore Corporation Adsorbent filter media for removal of biological contaminants in process liquids
US7875446B2 (en) * 2006-04-20 2011-01-25 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
PL2173861T5 (pl) * 2007-06-15 2017-10-31 Amgen Inc Sposoby obróbki nośnika kultury komórkowej do zastosowania w bioreaktorze
DK2307551T3 (en) 2008-06-18 2017-03-20 Oxford Biomedica (Uk) Ltd CLEANING RETROVIRAL VECTORS
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
JP2010207800A (ja) * 2009-02-16 2010-09-24 Kuraray Co Ltd ろ過ユニットおよびこれを備えたろ過装置
CA2777116C (en) * 2009-10-15 2020-09-01 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
JP5393896B2 (ja) * 2009-10-15 2014-01-22 クルセル ホランド ベー ヴェー アデノウイルス粒子の精製方法
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
JP5945270B2 (ja) 2010-07-20 2016-07-05 バヴァリアン・ノルディック・アクティーゼルスカブ 発現産物を採取するための方法
TWI503411B (zh) * 2010-08-11 2015-10-11 Nat Health Research Institutes Ｂ群腦膜炎球菌次單位疫苗之製造及純化
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5805908B2 (ja) 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP2984467B1 (de) * 2012-10-18 2020-10-14 Innovaprep LLC Flüssig-in-flüssig-biopartikel-fraktionierung und -konzentrierung
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN105339495A (zh) * 2013-07-11 2016-02-17 宝生物工程株式会社 制备无包膜病毒的方法
CN105612250A (zh) * 2013-10-07 2016-05-25 诺华股份有限公司 经处理的滤器
EP3105348B1 (de) * 2014-02-10 2019-08-21 Zymo Research Corporation Verfahren zur nukleinsäureerfassung
EP3151866B1 (de) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimäre kapside
US10023846B2 (en) 2014-07-10 2018-07-17 Takara Bio Inc. Production method for non-enveloped virus particles
EP3172317B1 (de) 2014-07-24 2019-05-01 Janssen Vaccines & Prevention B.V. Verfahren zur reinigung von poliovirus aus zellkulturen
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
KR102493350B1 (ko) * 2015-01-09 2023-01-27 다카라 바이오 가부시키가이샤 비엔벨로프 바이러스 입자의 제조방법
US9862936B2 (en) 2015-01-13 2018-01-09 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (AAV) and/or recombinant adeno-associated virus (rAAV) and gradients and flow-through buffers therefore
EP3054006A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten adeno-assoziierten viruspartikeln mittels mehrstufiger anionischer austauschchromatografie
EP3054007A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
JP6735288B2 (ja) 2015-04-14 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
IL301963A (en) 2016-07-21 2023-06-01 Spark Therapeutics Inc Scalable High Recovery Methods for High-Throughput Recombinant Adeno-Associated Viral Vector Production and Recombinant Adeno-Associated Viral Vectors Made So
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
CA3040288A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus purification methods
CN108085301B (zh) * 2016-11-22 2021-10-26 贺道耀 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
US10294452B2 (en) 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (de) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur aav-freisetzung
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
EP3697908A1 (de) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
EP3762500A1 (de) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome
JP7048889B2 (ja) * 2018-04-16 2022-04-06 日本電信電話株式会社 バクテリア産生セルロースカーボンの製造方法
WO2019209632A1 (en) 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
CA3098565A1 (en) 2018-04-29 2019-11-07 Claire G. ZHANG Scalable clarification process for recombinant aav production
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
SG11202011015QA (en) 2018-05-15 2020-12-30 Flagship Pioneering Innovations V Inc Fusosome compositions and uses thereof
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
US20210254103A1 (en) 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
CN112770812A (zh) 2018-07-24 2021-05-07 沃雅戈治疗公司 产生基因治疗制剂的系统和方法
EP3856762A1 (de) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin-expressionskonstrukte mit gentechnisch veränderten promotoren und verfahren zu deren verwendung
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
EP3880832A1 (de) 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosomzusammensetzungen zur verabreichung von hämatopoetischen stammzellen
AU2019378883A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
US20220008557A1 (en) 2018-11-14 2022-01-13 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
SG11202107645RA (en) 2019-01-18 2021-08-30 Voyager Therapeutics Inc Methods and systems for producing aav particles
EP3962536A1 (de) 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Systeme und verfahren zur herstellung von baculovirusinfizierten insektenzellen (biics) in bioreaktoren
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
EP4010465A1 (de) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
EP4022070A1 (de) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Kontrollierte expression viraler proteine
CN111394390A (zh) * 2020-03-26 2020-07-10 赛诺（深圳）生物医药研究有限公司 用于新型冠状病毒基因疫苗的批量生产重组腺病毒的方法
SI3919613T1 (sl) * 2020-06-05 2024-10-30 Sartorius Bia Separations D.O.O. Izboljšana izolacija adeno-asociiranega virusa za učinkovitejše odstranjevanje kontaminirane dna
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
RU2745307C1 (ru) * 2020-12-01 2021-03-23 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Способ очистки рекомбинантного аденовируса 26 серотипа (Ad26)
WO2022120176A2 (en) * 2020-12-04 2022-06-09 Gritstone Bio, Inc. Compositions and methods of use thereof
AR124306A1 (es) * 2020-12-10 2023-03-15 Astrazeneca Uk Ltd Métodos de purificación de adenovirus
WO2022137058A1 (en) * 2020-12-21 2022-06-30 Pfizer Inc. Methods and compositions for inhibiting excess nucleic acid precipitation
WO2022187473A2 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN115747017B (zh) * 2022-10-25 2023-06-09 上海华新生物高技术有限公司 一种腺病毒纯化装置
KR20250172833A (ko) * 2023-04-03 2025-12-09 젠자임 코포레이션 세포 용해를 위한 디바이스 및 이의 사용 방법
WO2024259672A1 (zh) * 2023-06-21 2024-12-26 上海金珂博生物技术有限公司 一种去除腺相关病毒载体颗粒中空载体颗粒的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
KR100461701B1 (ko) * 1996-02-29 2005-04-06 다카라 바이오 가부시키가이샤 바이러스의정제및제거방법
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
AU2001285263A1 (en) * 2000-08-25 2002-03-13 The General Hospital Corporation Selective precipitation of viruses
JP2004508064A (ja) 2000-09-15 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド コドン最適化ｈｉｖ１−ｇａｇ、ｐｏｌ、ｎｅｆおよび修飾体を発現する増強された第１世代アデノウイルスワクチン
ATE360683T1 (de) * 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus

Also Published As

Publication number Publication date
AU2003229060A1 (en) 2003-12-02
DE60335672D1 (de) 2011-02-17
EP1506287B1 (de) 2007-04-25
PT1506287E (pt) 2007-07-17
AU2003229060A8 (en) 2003-12-02
DK1506287T3 (da) 2007-08-20
DE60313451D1 (de) 2007-06-06
EP1506287A4 (de) 2005-06-08
WO2003097797A2 (en) 2003-11-27
DE60313451T2 (de) 2008-01-03
ES2285120T3 (es) 2007-11-16
EP1783212B1 (de) 2011-01-05
WO2003097797A3 (en) 2004-02-19
US20080118970A1 (en) 2008-05-22
ATE360683T1 (de) 2007-05-15
EP1783212A1 (de) 2007-05-09
US20050196854A1 (en) 2005-09-08
ES2357366T3 (es) 2011-04-25
US20050153420A1 (en) 2005-07-14
EP1506287A2 (de) 2005-02-16
US7326555B2 (en) 2008-02-05

Similar Documents

Publication Publication Date Title
ATE360683T1 (de) Verfahren zur reinigung von adenovirus
ATE346861T1 (de) Verfahren zur reinigung und isolierung von viren, aus pflanzenquellen
DE60039037D1 (de) Methode zur direkten sequenzierung von nukleinsäuren
ATE491790T1 (de) Isolierung und reinigung von nucleinsäuren
ATE377444T1 (de) Verfahren zur reduktion von mitgerissenen feststoffen und flüssigkeiten
ATE236183T1 (de) Verfahren zur reinigung von nukleinsäuren
ATE222229T1 (de) Verfahren zur rückgewinnung von fluorierten alkansäuren aus abwässern
DE69904986D1 (de) Methode zur Abtrennung und Wiedergewinnung von Polyethylenglykol und Siliziumkarbid-Schleifmittel zum Zwecke ihrer Wiederverwendung
DE602004030850D1 (de) Vorrichtung und Verfahren zur Trennung und Reinigung von Nucleinsäuren
ATE422542T1 (de) Magnetische isolierung und reinigung von nukleinsäuren
MX346184B (es) Resinas de amina-aldehido y sus usos en procesos de separacion.
SE8402861L (sv) Rening av biologiskt material
DE60131886D1 (de) Verfahren und vorrichtung zur wasserbehandlung
ATE175206T1 (de) Enzymatisches reinigungsverfahren
DE59905002D1 (de) Verfahren zur reinigung bzw. isolierung viraler nukleinsäuren
ATE492515T1 (de) Verfahren und vorrichtung zur reinigung von luft und wasser
WO2001094574A3 (en) Method and apparatus for purifying nucleic acids
ATE414147T1 (de) Nukleinsäurereinigung
ATE300501T1 (de) Verfahren zur entfernung von verunreinigungen in harnstoffhydrolysereaktoren
DE60311244D1 (de) Verfahren und automatische extraktion von nucleinsäuren aus komplexen mischungen
ATE389619T1 (de) Verfahren zur behandlung von industrieabwasserenthaltende organische schadstoffe
ATE410517T1 (de) Mittel und verfahren zur expression von homologen und heterologen proteinen in rhodococcus
ATE160098T1 (de) Verfahren zur reinigung von quarzsand und anderen materialien
ATE389627T1 (de) Kontinuierliches verfahren zur rückgewinnung von aceton aus einem abfallstrom der acetonreinigung
WO2002099128A3 (en) Sequence independent identification of viruses

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1783212

Country of ref document: EP